Cubist Systematic Strategies LLC Decreases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Cubist Systematic Strategies LLC cut its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 53.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 62,178 shares of the company’s stock after selling 70,186 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.17% of iTeos Therapeutics worth $478,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ITOS. SG Americas Securities LLC grew its stake in shares of iTeos Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after acquiring an additional 1,508 shares during the period. Wells Fargo & Company MN grew its stake in shares of iTeos Therapeutics by 16.9% in the fourth quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock worth $128,000 after acquiring an additional 2,402 shares during the period. Virtus ETF Advisers LLC grew its stake in shares of iTeos Therapeutics by 58.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after acquiring an additional 3,293 shares during the period. Empowered Funds LLC grew its stake in shares of iTeos Therapeutics by 5.0% in the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock worth $530,000 after acquiring an additional 3,305 shares during the period. Finally, Bridgeway Capital Management LLC grew its stake in shares of iTeos Therapeutics by 5.0% in the fourth quarter. Bridgeway Capital Management LLC now owns 69,072 shares of the company’s stock worth $530,000 after acquiring an additional 3,305 shares during the period. 97.16% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ITOS shares. Leerink Partnrs lowered shares of iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Piper Sandler restated an “overweight” rating and set a $12.00 target price (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday. Raymond James set a $12.00 target price on shares of iTeos Therapeutics in a research report on Wednesday. Wedbush restated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. Finally, HC Wainwright lowered shares of iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $17.86.

Insider Activity

In related news, major shareholder Ansbert Gadicke sold 1,031,931 shares of iTeos Therapeutics stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the sale, the insider now owns 3,452,797 shares in the company, valued at $27,829,543.82. This trade represents a 23.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the company’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the completion of the transaction, the insider now owns 2,108,594 shares in the company, valued at $16,995,267.64. This represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 12.50% of the company’s stock.

iTeos Therapeutics Trading Down 2.0%

Shares of ITOS opened at $7.81 on Friday. iTeos Therapeutics, Inc. has a twelve month low of $4.80 and a twelve month high of $18.70. The company has a market cap of $298.92 million, a P/E ratio of -2.48 and a beta of 1.39. The company’s fifty day simple moving average is $6.61 and its 200-day simple moving average is $7.42.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.14. Analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.